SCHEMBL6931033

SCHEMBL6931033

Cc1nc2c(Br)cccc2c(=O)[nH]1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 12/20 0.70
KDM4E B2RXH2 3/20 0.66
CYP1A2 P05177 1/20 0.66
CYP2D6 P10635 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
TNKS2 Q9H2K2 8/20 0.54
TNKS O95271 7/20 0.49
PARP2 Q9UGN5 2/20 0.49
NPC1 O15118 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
USP2 O75604 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
TYMS P04818 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30900892 1.00 PARP1 (0.70) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL1387263 0.82 PARP1 (1.00) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL29529679 0.79 PARP1 (1.00) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL1030410 0.79 TYMS (0.57) PARP1TNKS2TNKSPARP2TYMS
SCHEMBL15228758 0.79 PARP1 (0.49) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL15840543 0.79 PARP1 (1.00) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL215530 0.79 PARP1 (1.00) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL526074 0.79 PARP1 (0.70) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL15045613 0.78 PARP1 (0.78) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL15840747 0.78 PARP1 (0.68) PARP1KDM4ECYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452480-A1 SUBSTITUTED PYRROLO[1,2- ]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Lysosomal Therapeutics Inc. (US) 2019-03-13 EP disclosed
WO-2017192929-A1 SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2017-11-09 WO disclosed
WO-2011012622-A1 BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2011-02-03 WO disclosed